Galderma Announces DREAM Study Results With Dysport

Galderma announces results of their DREAM study using Dysport twice-yearly for a natural reduction in glabellar lines.

Today, Galderma announced the results of their Dysport Real-World Evaluation and Measured (DREAM) satisfaction study that evaluated patient satisfaction and safety with a twice-yearly Dysport injection schedule.

“Dysport is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age,” according to the press release announcing the study results.

The phase 4 open-label, multicenter, interventional DREAM study included 120 patients 18 to 65 years of age with moderate to severe glabellar lines at maximum frown expression. A total of 90% of the patients were female, with 33% toxin naïve.

Patients received Dysport injections at the start of the study and six months later. They were then assessed six months after that, at the 12-month mark after the study began.

Satisfaction was the study’s primary endpoint. Patients were asked to report being “highly satisfied,” “satisfied,” “dissatisfied” or “highly dissatisfied” at the 12-month assessment. Satisfaction was also measured secondarily with the 5-point Likert questionnaire and FACE-Q scales.

The study revealed that 95% of patients were satisfied (35%) or highly satisfied (60%) at the 12-month assessment. A total of 97% of the 35 toxin-naïve patients and 93% of patients previously treated with toxin were “satisfied” or “highly satisfied” at 12 months.

Secondary findings included measures of natural appearance, self-perception and brand loyalty. According to 97% of patients, the treatment looked natural at 12 months, while 85% were “satisfied” or “highly satisfied” with their appearance at 12 months vs. 51% at baseline. At the 12-month assessment, 98% of patients reported wanting to receive the same treatment again and 97% would recommend the treatment to family and friends.

Treatment-related adverse events were minimal, with only one patient (0.8%) who experienced mild injection site bruising.

"Today's announcement underscores our commitment to growing the aesthetic market and continuing to drive innovation so that patients can embrace injections with confidence," said Alisa Lask, Vice President and General Manager of Galderma U.S. Aesthetics in the release. "We are thrilled with the top-line findings from the DREAM study demonstrating high levels of patient satisfaction and natural-looking results with Dysport when given twice a year. We anticipate publishing full results from DREAM, the first clinical study to evaluate this treatment schedule, in the coming months."